J
Jiaxing Antikang Biotechnology
A drug developer focused on respiratory anti-infections
About Jiaxing Antikang Biotechnology
Jiaxing Antikang Biotechnology, established on June 26, 2018, is a clinical-stage pharmaceutical company concentrating on the development of small molecule therapeutics for respiratory infections and pain management. The firm is guided by a seasoned leadership team with deep roots in pharmaceutical sciences. Chairman Jiang Weiping holds a Ph.D. in Pharmacy from China Pharmaceutical University and brings 39 years of comprehensive experience in drug research and development, production, and management. He is joined by co-founder and CEO, Zhu Xiaoyun, who holds a doctorate in medicinal chemistry. Their collective expertise forms the foundation of the company's scientific direction and strategic operations.
The company's business model is centered on the in-house research, development, and eventual commercialization of a pipeline of drug candidates that address unmet clinical needs. By leveraging a technology platform focused on metabolically differentiated small molecules, Antikang has established a technical barrier in areas like innovative drug design, DMPK (Drug Metabolism and Pharmacokinetics) technology research, and the development of formulations for special patient populations, such as children. The company's revenue generation will be contingent on the successful clinical development and market approval of its products, likely through direct sales and potential licensing or partnership agreements. The company's scientific and research team is further strengthened by the leadership of several academicians.
Antikang Biotechnology's product pipeline features several promising candidates. Its lead asset is ADC189 (Madeuteranovir), a novel anti-influenza drug designed for a "one-time cure." This drug has shown significant clinical progress in trials for both adults and children, with formulations in tablets and granules. Beyond influenza, the pipeline includes ADC789, a suspension for treating Respiratory Syncytial Virus (RSV); ADC101, a new-generation super-antibiotic for mycoplasma infections; and ADC308, a tablet aimed at treating endometriosis and uterine fibroids, a condition with limited treatment options in the domestic market. The company has successfully raised significant capital to advance these programs, completing an A-round financing of over 200 million yuan in June 2024, followed by an A+ round in September 2025, with participation from notable investors including Simcere Pharmaceutical, Huajin Investment, and existing shareholder Co-stone Capital.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Open positions
- None listed
- Dealroom signal
- 19.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotechnology, Biotech and Pharma, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
- Website
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES A✓Equity / VC | Jun 2024 | $28M | $138M | Wenzhou Capital · Jiarui future star · Songze Capital · Shunjie Health | ↗ |
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Jiaxing Antikang Biotechnology in the Kaohsiung ecosystem
The Jiaxing Antikang Biotechnology office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Simcere Pharma- HIHuajin Investment
- WCWenzhou Capital
- JSJiarui future star
- SCSongze Capital
- SHShunjie Health
- HAHuajin Avenue
- JCJiaxing New Venture Capital
Cowin Capital
GSR United Capital
Source: Dealroom Talent Intelligence.
Global footprint
Market sentiment
An AI-synthesised read of the highest-engagement posts about Jiaxing Antikang Biotechnology on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Jiaxing Antikang Biotechnology’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.









